About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Biomedical Research in Melanoma group is interested in skin cancer. We investigate the molecular causes for these diseases to design effective therapies against them. Our research is done in close proximity to patients, where our goal is to translate our discoveries as fast as possible to the clinic. To that end, we have a multidisciplinary group that associate dermatologists, oncologists, pathologists and basic-scientists that ask relevant clinical questions that need biological answers. Our workflow contemplates information obtained from patients (genetic information, clinical history, functional data…) that is translated into animal models (genetic modified mouse models, PDX…) and in vitro experiments to answer the formulated questions. These results are used to design novel therapeutic approaches, including drug development and preclinical studies that ultimately will be translated to patients.
The main lines of investigation are: • Molecular mechanisms involved in melanoma development and progression, • Targeting metabolism for melanoma treatment, • The mechanisms of resistance to immunotherapy.
IP: Juan Angel Recio Conde Collaborators: Paula Granado Martinez, Kimberley Anne McGrail Fernández, Carlos González Cruz, Vicente García-Patos Briones Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 60000 Reference: 2021 SGR 00653 Duration: 01/01/2022 - 30/06/2025
IP: Juan Angel Recio Conde Collaborators: Paula Granado Martinez, Judit Álvarez González Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 63589.78 Reference: 2021 FI_B 00017 Duration: 01/04/2021 - 31/03/2024
IP: Juan Angel Recio Conde Collaborators: Paula Granado Martinez, Kimberley Anne McGrail Fernández, Vicente García-Patos Briones, Berta Ferrer Fábrega, Sara Garcia Ortega Funding agency: Instituto de Salud Carlos III Funding: 341220 Reference: PI20/00384 Duration: 01/01/2021 - 30/04/2024
IP: Cristina Solé Marce Collaborators: Berta Ferrer Fábrega, Gloria Aparicio Español Funding agency: Instituto de Salud Carlos III Funding: 99099 Reference: PI21/01869 Duration: 01/01/2022 - 31/12/2024
PMID: 37830789 Journal: PEDIATRIC DERMATOLOGY Year: 2023 Reference: Pediatr Dermatol. 2023 Oct 13. doi: 10.1111/pde.15447. Impact factor: Publication type: Paper in international publication Authors: Aracil, Belen; Calvo-Montes, Jorge; Canada-Garcia, Javier E; Canton, Rafael; Casquero-Garcia, Veronica; Cercenado, Emilia; El Mammery, Achraf; Ferrandiz-Pulido, Carla; Garcia-Cobos, Silvia; Garcia-Patos, Vicente et al. DOI: 10.1111/pde.15447
PMID: 37828676 Journal: CURRENT MEDICINAL CHEMISTRY Year: 2023 Reference: Curr Med Chem. 2023 Oct 11. doi: 10.2174/0109298673268775231003111540. Impact factor: Publication type: Paper in international publication Authors: Andrade, Fernanda; Duran-Lara, Esteban F; Ferrandiz-Pulido, Carla; Garcia-Patos, Vicente; Gonzalez-Cruz, Carlos; Lobos G, Olga; Navarro, Alexandra; Rafael, Diana; Repiso, Trinidad; Vijayakumar, Sekar et al. DOI: 10.2174/0109298673268775231003111540
PMID: 37929250 Journal: Year: 2023 Reference: Ultrasound. 2023 Nov;31(4):292-299. doi: 10.1177/1742271X231157618. Epub 2023 Mar 17. Impact factor: Publication type: Paper in international publication Authors: Albert, Eliseo; Amat, Paula; Balaguer, Aitana; Barba, Pere; Beas, Francisco; Benzaquen, Ana; Bradbury, Melissa; Campos, Diana; Capell-Morell, Montserrat; Carpio, Cecilia et al. DOI: 10.1177/1742271X231157618
PMID: 38013065 Journal: CANADIAN JOURNAL OF CARDIOLOGY Year: 2023 Reference: Can J Cardiol. 2023 Nov 25:S0828-282X(23)01952-9. doi: 10.1016/j.cjca.2023.11.025. Impact factor: Publication type: Paper in international publication Authors: Abadias-Granado, Isabel; Aguasca, Gerard Marti; Almagro, Manuel; Almenara-Blasco, Manuel; Alujas, Teresa Gonzalez; Arias-Santiago, Salvador; Banuls, Jose; Barcelo, Maria Calvo; Barrabes, Jose A; Belahnech, Yassin et al. DOI: 10.1016/j.cjca.2023.11.025
PMID: 30226477 Journal: Indian Journal of Dermatology Venereology & Leprology Year: 2020 Reference: Indian J Dermatol Venereol Leprol. 2020 Mar-Apr;86(2):215-217. doi: 10.4103/ijdvl.IJDVL_13_18. Impact factor: 2.712 Publication type: Paper in international publication Authors: Gonzalez-Cruz, Carlos, Bodet, Domingo, Garcia-Patos, Vicente et al. DOI:
On World Cancer Research Day, we highlight the oncology research model of the Vall d'Hebron Campus that allows laboratory results to be transferred as quickly as possible to clinical practice.
Dr. Vicente García-Patos received an outstanding career award and his team: a prize for the best oral communication and a first accessit for the best poster in oncology
Júlia Baguña, Andrea Guala i Roberto Orsenigo han rebut una dels 105 ajuts concedits en el marc del programa INPhINIT i les 40 del programa Junior Leader.
